This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals
AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU
by Zacks Equity Research
AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives approval in Europe for treating rheumatoid arthritis under the trade name of Rinvoq.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More
by Zacks Equity Research
The biotech sector was in focus this week with pipeline and regulatory updates from quite a few players.
Biogen's Gosuranemab Fails in Phase II Brain Disorder Study
by Zacks Equity Research
Biogen's (BIIB) gosuranemab fails to meet primary endpoint in a phase II study evaluating gosuranemab (BIIB092) in patients with progressive supranuclear palsy, a degenerative brain disorder.
J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH
by Zacks Equity Research
J&J's (JNJ) initial data on CAR-T therapy candidate JNJ-68284528 from an early-stage study shows promising response rate.
Biogen Up on New Data on Alzheimer's Candidate Aducanumab
by Zacks Equity Research
Biogen (BIIB) divulges new positive data on Alzheimer's candidate, aducanumab at CTAD. Stock rises.
Aurinia's Lupus Candidate Succeeds in Pivotal Study, Stock Up
by Zacks Equity Research
Aurinia's (AUPH) lupus candidate, voclosporin, met primary endpoint of renal response rate in a late-stage study. An NDA is expected in the first half of 2020.
Biogen's Lupus Candidate Meets Endpoint in Phase II Study
by Zacks Equity Research
Biogen (BIIB) posts favorable top-line results from a phase II study evaluating BIIB059 for treating cutaneous and systemic lupus erythematosus. The study tastes success by achieving its main goal.
Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
Biogen's Shares Down on Rating Downgrade by Baird Analyst
by Zacks Equity Research
Biogen's (BIIB) shares decline following a rating downgrade by an analyst at Robert W. Baird on concerns related to approval of Alzheimer's disease candidate, aducanumab.
Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates.
ChemoCentryx Up on Encouraging Rare Disease Candidate Data
by Zacks Equity Research
ChemoCentryx (CCXI) announces positive data pivotal study evaluating its lead candidate, avacopan, in patients with ANCA vasculitis, a rare disease affecting small blood vessels.
The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal
by Kinjel Shah
Here are four stocks that boast promising prospects and are most likely to be takeout targets.
Roche's NDA for SMA Drug Risdiplam Gets Priority Review
by Zacks Equity Research
The FDA accepts Roche's (RHHBY) NDA for risdiplam under a priority review to treat spinal muscular atrophy. A verdict is pending on May 24, 2020.
Biogen Ends Enrollment in Eye Disorder Study on Gene Therapy
by Zacks Equity Research
Biogen (BIIB) completes enrollment in the global phase III STAR clinical study evaluating the gene therapy timrepigene emparvovec for the treatment of a rare, inherited retinal disorder.
AstraZeneca Gets FDA Nod for Calquence Line Extension in CLL
by Zacks Equity Research
The FDA approves AstraZeneca's (AZN) Calquence to treat CLL patients, based on positive data from two phase III studies.
Healthcare ETF (RYH) Hits New 52-Week High
by Sanghamitra Saha
This healthcare ETF hits a new 52-week high. Are more gains in store for this ETF?
4 Big Biotech Stocks Worth Considering Post Q3 Earnings
by Zacks Equity Research
We highlight a few principal players from the biotech sector, which are likely to witness a winning run in the near term.
Top & Flop ETFs Halfway Through Q4
by Sweta Killa
The fourth quarter brings strong gains for Wall Street buoyed by easing U.S.-China trade worries, stronger-than-expected corporate earnings and Fed's third rate cut.
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks
by Sanghamitra Saha
Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.
Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
Roche's SMA Drug Meets Primary Endpoint in Pivotal Study
by Zacks Equity Research
Roche's (RHHBY) risdiplam meets primary endpoint in SUNFISH study in SMA patients.